Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed (Eli Lilly and Company)
- Development stage
- Approved
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Pemetrexed is a small molecule chemotherapy drug classified as an antifolate antineoplastic agent. It is primarily used to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC), either alone or in combination with other agents such as cisplatin or pembrolizumab[1][2][3]. Pemetrexed works by inhibiting several folate-dependent enzymes essential for DNA and purine synthesis—specifically thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT)[3][6][8]. This inhibition disrupts DNA replication and repair in rapidly dividing cancer cells. The drug is administered intravenously, typically every 21 days, and patients often receive supplemental folic acid, vitamin B12, and corticosteroids to reduce side effects[2][5]. Pemetrexed was developed by Eli Lilly and Company.
- Brand names
- AlimtaPemfexyPemrydi RTUAxtle
- Other names
- pemetrexed disodium
02
Targets
GART (GAR transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed (Eli Lilly and Company).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed (Eli Lilly and Company).